IDH1 and astrocytoma (excluding glioblastoma): Using niacin (a NAD+ prodrome compound) a phase I/II clinical trial has been initiated to evaluate whether the addition of niacin along with the standard temozolomide and radiation therapy treatment will provide a significant effect in IDH-mutant astrocytoma grade 4 (NCT04677049).